Irritable Bowel Syndrome

Gastroenterology·MeSH: Irritable Bowel Syndrome

Prevalence

11200.0 / 100K

Incidence

400.0 / 100K/yr

19 drugs in development·13 companies·6 clinical trials

Drug Pipeline by Phase

Approved(9)

Drug	Company
chlordiazepoxide	Amneal Pharmaceuticals, Inc. (AMRX)
dicyclomine	NEXUS BIOPHARMA INC (NEXS)
donnatal	Societal CDMO, Inc. (SCTL)
IBSRELA	ARDELYX, INC. (ARDX)
inFoods® (IBS)	BIOMERICA INC (BMRA)
LINZESS	IRONWOOD PHARMACEUTICALS INC (IRWD)
trulance	SYNERGY PHARMACEUTICALS LLC (SGYP)
Trulance	Bausch Health Companies Inc. (BHC)
Xifaxan	Bausch Health Companies Inc. (BHC)

Phase 3(2)

Drug	Company
tenapanor (CIC label extension / ACCEL (ten-03-301))	ARDELYX, INC. (ARDX)
tenapanor 25 mg bid	ARDELYX, INC. (ARDX)

Phase 2(3)

Drug	Company
DS-01	Valneva SE (VALN)
olorinab	ARENA PHARMACEUTICALS INC (ARNA)
tenapanor	ARDELYX, INC. (ARDX)

Phase 1(2)

Drug	Company
LY3537031	ELI LILLY & Co (LLY)
Trimedat®	Crinetics Pharmaceuticals, Inc. (CRNX)

Unknown(3)

BioSniper tracks 19 drugs in development for Irritable Bowel Syndrome across 13 companies.

There are 6 clinical trials targeting Irritable Bowel Syndrome tracked by BioSniper.

The estimated prevalence of Irritable Bowel Syndrome is approximately 11200.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.